drugset / Trial / NCT02345304
Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin
Non-randomizedCrossoverOpen-labelTreatment
Summary
To assess the influence of different dose strengths of BI 1181181 on single dose kinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)
Timeline
- Start
- 2015-03
- Primary completion
- 2015-04
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1181181 | Unknown | — | — |
| Subject | Digoxin | Other / unclassified | — | — |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Omeprazole | Other / unclassified | — | — |
| Subject | Warfarin | Small molecule | — | — |
Indications
No indication recorded.